Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers



Status:Completed
Conditions:Gastrointestinal, Podiatry, Diabetes
Therapuetic Areas:Endocrinology, Gastroenterology, Orthopedics / Podiatry
Healthy:No
Age Range:18 - 80
Updated:11/30/-0001
Start Date:April 2012
End Date:January 2014
Contact:Sharron E McCulloch, MS, CCRP
Email:smcculloch@osiris.com
Phone:443-545-1830

Use our guide to learn which trials are right for you!

A Multicenter, Adaptive Design, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Grafix® for the Treatment of Chronic Diabetic Foot Ulcers


The primary objective of the present study is to further establish in a randomized
controlled trial, the safety and efficacy of weekly Grafix® administration versus control in
patients with chronic diabetic foot ulcers. The primary endpoint is complete wound closure
of the index wound, defined as 100% re-epithelialization as determined by the Investigator.

Grafix® is a product regulated for use in the US by the FDA as a Human Cellular and Tissue
Based Product (HCT/P) under Title 21 CFR Part 1271.


The treatment indication is for chronic, diabetic foot ulcers (DFUs) between 1cm2 and 15cm2
located below the malleoli on the plantar or dorsal surface of the foot. Patients must have
confirmed Type I or Type II Diabetes.

Patients will receive treatment every week for 12 weeks duration in the Single-Blind
Treatment phase of the trial.

Patients who receive Grafix® or control will be evaluated for primary efficacy up to 84
days, and for safety and wound re-occurrence for 84 days after wound closure. Patients in
the control group whose wounds are not closed at the end of treatment may be offered Grafix®
in an Open-Label Treatment phase. The Open-Label Treatment phase can last up to an
additional 84 days.

Inclusion Criteria:

1. Between 18 years and 80 years of age inclusive, as of the date of screening

2. Confirmed diagnosis of Type I or Type II Diabetes

3. An Index Ulcer defined as chronic (presence of wound for > 4 weeks) but not present
for more than 52 weeks at the Screening Visit

4. Index Ulcer is located below the malleoli on the plantar or dorsal surface of the
foot

5. The Index Ulcer is between 1cm2 and 15 cm2 at the Screening Visit

6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of
exposed muscle, tendon, bone, or joint capsule

7. Wound is free of necrotic debris

8. Patient has adequate circulation to the foot as documented by either:

- Ankle Brachial Index (ABI) > 0.70 and < 1.30, or

- In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30, a Toe
Brachial Index (TBI) ≥ 0.50

- In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30 and TBI
cannot be performed (e.g., toe is absent, wounds are present, or site cannot
perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis
arteries at the ankle consistent with adequate flow in the foot (biphasic or
triphasic) and other diagnostic confirmation of adequate flow (e.g., duplex
imaging, normal pulse volume recording [PVR] testing).

Exclusion Criteria:

1. Index Ulcer is of non-diabetic pathophysiology

2. Gangrene is present on any part of the affected foot

3. Index Ulcer is over an active Charcot deformity

4. The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit

5. Patient is currently receiving dialysis

6. Patient has a glycated hemoglobin A1c (HbA1c) level of > 12%

7. Chronic oral steroid use > 7.5 mg daily

8. Requiring intravenous (IV) antibiotics to treat the index wound infection

9. Patient has an ulcer within 15cm of the Index Ulcer identified for study
consideration

10. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or
cytotoxic agents

11. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune
Deficiency Syndrome (AIDS)

12. Current evidence of osteomyelitis, cellulitis, or other evidence of infection
including fever or pus drainage from the wound site

13. Patient has active malignancy other than non-melanoma skin cancer

14. Patient's Index Ulcer has decreased by ≥ 30% during 1-week screening period as
determined by criteria provided by the Wound Core Lab

15. Patient's random blood sugar is > 450 mg/dl at screening

16. Patient has untreated alcohol or substance abuse at the time of screening

17. Pregnant women

18. Patient is currently enrolled or participated in another investigational device,
drug, or biological trial within 60 days of screening

19. Patient has allergy to primary or secondary dressing materials used in this trial

20. Patient has had within the last 30 days, or is currently undergoing, or is planning
for wound treatments with enzymes, growth factors, living skin, dermal substitutes or
other advanced biological therapies
We found this trial at
15
sites
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
400 Bald Hill Road
Warwick, Rhode Island 02886
401-739-9350
?
mi
from
Warwick, RI
Click here to add this to my saved trials
Altoona, Pennsylvania 16602
?
mi
from
Altoona, PA
Click here to add this to my saved trials
Augusta, Georgia 30809
?
mi
from
Augusta, GA
Click here to add this to my saved trials
CHapel Hill, North Carolina 27599
?
mi
from
CHapel Hill, NC
Click here to add this to my saved trials
Columbus, Ohio 43214
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Encinitas, California 92024
?
mi
from
Encinitas, CA
Click here to add this to my saved trials
Glendale, Arizona 85306
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
Inverness, Florida 34452
?
mi
from
Inverness, FL
Click here to add this to my saved trials
Jacksonville, Florida 32207
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Montgomery, AL
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Toms River, New Jersey 08753
?
mi
from
Toms River, NJ
Click here to add this to my saved trials